Nanoparticles of alkylglyceryl dextran and poly(ethyl cyanoacrylate) for applications in drug delivery: Preparation and characterization
Source abstract
Abstract
Toward the development of drug carriers that are capable of crossing biological membranes, controlled emulsion polymerization has been utilized to produce nanoparticulate carriers from the combination of poly(alkyl cyanoacrylate) and alkylglyceryl dextran to a molecular structure designed to combine the nonimmunogenic and stabilizing properties of dextran with the demonstrated permeation enhancing ability of alkylglycerols. To this aim, a systematic series of alkylglyceryl dextrans have been synthesized and functionalized with ethyl or butyl cyanoacrylates to form stable polymeric nanocarriers (100–500 nm). Results of investigations into their capability to act as controlled-release devices and their cytotoxicity against bEnd3 cells are reported.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmacy and Biomedical Sciences, University of Portsmouth, St Michael’s Building, Portsmouth, United Kingdom
Department of Medical Biochemistry, University of Nigeria Enugu Campus (UNEC), Enugu, Nigeria
Institute of Marine Sciences, University of Portsmouth, Portsmouth, United Kingdom
Funding
Daniel M. Ibegbu thanks the Nigerian Tertiary Education Trust Fund (TETFUND) and the University of Nigeria, Nsukka, for their financial assistance (PhD studentship).
References (58)
Show source-provided references
1. 10.1158/1078-0432.CCR-06-285410.1158/1078-0432.CCR-06-2854 ↗
2. 10.1016/j.nbd.2009.07.02810.1016/j.nbd.2009.07.028 ↗
3. 10.1016/j.addr.2013.08.00810.1016/j.addr.2013.08.008 ↗
4. Alyautdin R. · Int. J. Nanomed · 2014 · 9 · 795
5. 10.1016/S0165-0173(01)00083-210.1016/S0165-0173(01)00083-2 ↗
6. 10.1023/A:100704980666010.1023/A:1007049806660 ↗
7. 10.1097/00006123-199805000-0008210.1097/00006123-199805000-00082 ↗
8. 10.1371/journal.pone.003256810.1371/journal.pone.0032568 ↗
9. 10.1007/s11095-007-9374-510.1007/s11095-007-9374-5 ↗
10. 10.1002/pola.2238810.1002/pola.22388 ↗
11. 10.1016/j.ijpharm.2003.06.00310.1016/j.ijpharm.2003.06.003 ↗
12. 10.1007/978-1-4614-0881-9_1110.1007/978-1-4614-0881-9_11 ↗
13. 10.1016/j.tips.2009.08.00410.1016/j.tips.2009.08.004 ↗
14. 10.1021/js980084y10.1021/js980084y ↗
15. 10.1016/j.addr.2012.09.02210.1016/j.addr.2012.09.022 ↗
16. 10.1016/j.ijpharm.2005.03.03110.1016/j.ijpharm.2005.03.031 ↗
17. Martins S. · Int. J. Nanomed · 2007 · 2 · 595
18. 10.1586/17434440.5.1.4110.1586/17434440.5.1.41 ↗
19. 10.1023/A:102260412095210.1023/A:1022604120952 ↗
20. 10.1016/j.colsurfb.2011.11.02910.1016/j.colsurfb.2011.11.029 ↗
21. 10.1023/A:101898390453710.1023/A:1018983904537 ↗
22. 10.1023/A:101894720859710.1023/A:1018947208597 ↗
23. 10.1016/0378-5173(92)90210-S10.1016/0378-5173(92)90210-S ↗
24. 10.1016/S0169-409X(03)00041-310.1016/S0169-409X(03)00041-3 ↗
25. 10.1007/BF0087724510.1007/BF00877245 ↗
26. 10.1021/ma034097w10.1021/ma034097w ↗
27. 10.1023/A:101648691071910.1023/A:1016486910719 ↗
28. 10.3109/1061186000899686210.3109/10611860008996862 ↗
29. 10.1016/j.carbpol.2012.09.09810.1016/j.carbpol.2012.09.098 ↗
30. 10.1007/s00221000055310.1007/s002210000553 ↗
31. 10.1046/j.1365-201X.2002.01037.x10.1046/j.1365-201X.2002.01037.x ↗
32. 10.1038/sj.bjp.070555410.1038/sj.bjp.0705554 ↗
33. 10.1111/bph.1221810.1111/bph.12218 ↗
34. 10.1016/j.actbio.2015.05.00910.1016/j.actbio.2015.05.009 ↗
35. 10.1006/abio.2000.469910.1006/abio.2000.4699 ↗
36. 10.2147/IJN.S3873710.2147/IJN.S38737 ↗
37. 10.1021/ma00170a01710.1021/ma00170a017 ↗
38. 10.1016/j.carbpol.2013.03.01010.1016/j.carbpol.2013.03.010 ↗
39. 10.1016/j.ijbiomac.2013.04.04610.1016/j.ijbiomac.2013.04.046 ↗
40. 10.1016/j.carbpol.2013.08.00410.1016/j.carbpol.2013.08.004 ↗
41. 10.1007/s00216-009-3013-410.1007/s00216-009-3013-4 ↗
42. De Belder, A. N. Dextran, Report No. 18–1166-12; Amersham Bioscience, Chalfont, England, 2003.
43. 10.1016/j.ejpb.2007.04.01510.1016/j.ejpb.2007.04.015 ↗
44. 10.1016/S0142-9612(00)00375-610.1016/S0142-9612(00)00375-6 ↗
45. 10.1016/j.polymer.2005.11.09110.1016/j.polymer.2005.11.091 ↗
46. 10.1016/j.polymer.2004.11.06710.1016/j.polymer.2004.11.067 ↗
47. 10.1016/0378-5173(95)04305-510.1016/0378-5173(95)04305-5 ↗
48. 10.1021/ac00099a02910.1021/ac00099a029 ↗
49. 10.1002/(SICI)1098-2787(1999)18:6<349::AID-MAS1>3.0.CO;2-H10.1002/(SICI)1098-2787(1999)18:6<349::AID-MAS1>3.0.CO;2-H ↗
50. 10.3390/molecules1705495010.3390/molecules17054950 ↗
51. 10.1016/j.ijpharm.2010.03.06310.1016/j.ijpharm.2010.03.063 ↗
52. 10.1016/S0141-3910(02)00113-110.1016/S0141-3910(02)00113-1 ↗
53. 10.1016/0378-5173(92)90209-K10.1016/0378-5173(92)90209-K ↗
54. 10.1016/0378-5173(94)90086-810.1016/0378-5173(94)90086-8 ↗
55. 10.1007/s11095-011-0510-x10.1007/s11095-011-0510-x ↗
56. 10.1016/0142-9612(90)90084-410.1016/0142-9612(90)90084-4 ↗
57. 10.1023/A:101205950194710.1023/A:1012059501947 ↗
58. Pitaksuteepong T. · Pharmazie · 2004 · 59 · 134